Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 1

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 7, 2014; 20(1): 235-241
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235

Table 1 Patients’ general characteristics n (%)

	Numbers
Age (range), yr	53¹ (36-71)
Sex
Male	25 (81)
Female	6 (19)
Etiology
HBV	26 (83.9)
HCV	1 (3.2)
Others	4 (12.9)
Status of primary liver mass
Stable	13 (41.9)
Progressive	18 (58.1)
Metastatic sites
Lung	28 (90.3)
Lymph node	10 (32.3)
Bone	8 (25.1)
Peritoneum	3 (9.7)
Previous treatment before sorafenib
TACE	29 (93.5)
Surgery	17 (54.8)
Radiation	12 (38.7)
Hepatic arterial infusion	9 (29.0)
Radiofrequency ablation	5 (16.1)

¹Median. TACE: Transarterial chemoembolization; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Citation: Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
URL: https://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i1.235

Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241 [PMID: 24415877 DOI: 10.3748/wjg.v20.i1.235]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.